# Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

> **NCT01201811** · PHASE4 · COMPLETED · sponsor: **Celgene** · enrollment: 44 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01201811
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2013-05-01
- **Final completion:** 2013-05-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201811, "Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01201811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*